Tag: attorneys

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.

NEW YORK, June 07, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.

NEW YORK, June 07, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GoHealth, Inc. (NASDAQ: GOCO) resulting from allegations that GoHealth may have issued materially misleading business information to the investing public.

New York, NY, June 07, 2025 (GLOBE NEWSWIRE) -- Goldstein Patent Law, a national leader in patent law, is happy to announce it has recently published a new article on How to patent an idea. Leveraging the expertise and nearly 30 years of experience from the founder of the law firm and principal patent attorney Rich Goldstein, the new insights answer the question, “Can a concept be patented?” and help to demystify IP rights, how to secure patent protection and how intellectual property attorneys can help navigate the process.

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as certain of Zenas BioPharma’s top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BigBear.ai Holdings, Inc. (NYSE: BBAI) between March 31, 2022 and March 25, 2025, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Provident Bancorp, Inc. (NASDAQ: PVBC) to NB Bancorp, Inc. is fair to Provident shareholders. Under the terms of the proposed transaction, Provident shareholders will receive for each share of Provident common stock, at the holder’s election, either (i) 0.691 shares of NB Bancorp common stock or (ii) $13.00 in cash.

URGN Investors with Losses Encouraged to Contact Hagens Berman

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar Corporation (NASDAQ: SATS) focused on whether EchoStar and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.